Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1914-1920

  Han, Tae H ^a   Zhao, Baiteng ^b  

^a Stemcentrx   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; SGN 30; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VEDOTIN;

AREA UNDER THE CURVE RATIO; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; TISSUE DISTRIBUTION;

ANIMALS; DRUG STABILITY; HUMANS; IMMUNOCONJUGATES; TISSUE DISTRIBUTION;

EID: 84930882754     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058586     Document Type: Short Survey

References (64)

1. Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, and Esue O (2014) Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem 25:656-664.
2. Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, and Benjamin DR (2009) The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330:932-938.
3. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, Bernstein SH, Bociek RG, Lorenz JM, and Hart BW, et al. (2008) A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111:1848-1854.
4. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, and Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162-2171.
5. Beckley NS, Lazzareschi KP, Chih HW, Sharma VK, and Flores HL (2013) Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem 24:1674-1683.
6. Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, and Ulufatu S, et al. (2013) An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. Br J Pharmacol 168:445-457.
7. Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P, Khawli LA, and Lin K (2012) Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 53:1454-1461.
8. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, and Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21:2153-2163.
9. Boylan NJ, Zhou W, Proos RJ, Tolbert TJ, Wolfe JL, and Laurence JS (2013) Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates. Bioconjug Chem 24:1008-1016.
10. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, and Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-1496.
11. Burke PJ, Hamilton JZ, Hunter JH, Jeffrey SC, Doronina SO, Okeley NM, Meyer DW, Senter PD, and Lyon RP (2014) Development and pharmacological properties of PEGylated glucuronideauristatin linkers, Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Abstract 1786, AACR, Philadelphia.
12. Burris HA, 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, and Girish S, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405.
13. Carter PJ and Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169.
14. Center for Drug Evaluation and Research (CDER) (2011) Clinical Pharmacology and Biopharmaceutics Review(s). Application Number: 125388Orig1s000. U.S. Food and Drug Administration, Beltsville, MD.
15. Center for Drug Evaluation and Research (CDER) (2013) Clinical Pharmacology and Biopharmaceutics Review(s). Application Number: 125427Orig1s000. U.S. Food and Drug Administration, Beltsville, MD.
16. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, and Rosania GR, et al.; International Transporter Consortium (2013) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94:126-141.
17. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, and Lieberman G, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
18. Davis JA, Rock DA, Wienkers LC, and Pearson JT (2012) In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos 40:1927-1934.
19. Decarvalho S, Rand HJ, and Lewis A (1964) Coupling of cyclic chemotherapeutic compounds to immune gamma-globulins. Nature 202:255-258.
20. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, and Siegall CB, et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784.
21. Ducry L and Stump B (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5-13.
22. Erickson HK and Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14: 799-805.
23. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, and Pinkas J, et al. (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133-1142.
24. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, and Blättler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433.
25. Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, and Zhang L (2013) Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos 41:1598-1609.
26. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, and Sievers EL, et al. (2009) A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171-179.
27. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, and Saad O, et al. (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229-1240.
28. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, and Siguenza P (2013) Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5:997-1006.
29. Guo J, Kumar S, Prashad A, Starkey J, and Singh SK (2014) Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol-maleimide chemistry. Pharm Res 31:1710-1723.
30. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, and Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063-7070.
31. Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, and Lynch CM, et al. (2013a) CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol 53:866-877.
32. Han TH, Grove LE, and Lynch CM (2013b) Effect of renal impairment on the pharmacokinetics of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies (Abstract). Clin Pharmacol Ther 93:S17.
33. Hengel SM, Sanderson R, Valliere-Douglass J, Nicholas N, Leiske C, and Alley SC (2014) Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal Chem 86:3420-3425.
34. Herbertson RA, Tebbutt NC, Lee FT, Macfarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, and Smyth FE, et al. (2009) Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 15:6709-6715.
35. Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, and Lesko LJ (2010) Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 87:497-503.
36. Jackson D, Atkinson J, Guevara CI, Zhang C, Kery V, Moon SJ, Virata C, Yang P, Lowe C, and Pinkstaff J, et al. (2014) In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE 9:e83865.
37. Jager E, van der Velden VH, te Marvelde JG, Walter RB, Agur Z, and Vainstein V (2011) Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS ONE 6:e24265.
38. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, and Dennis MS, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932.
39. Kaur S (2013) Bioanalysis special focus issue on antibody-drug conjugates. Bioanalysis 5:981-983.
40. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, and Ab O, et al. (2010) Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70:2528-2537.
41. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, and Sliwkowski MX, et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704.
42. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, and Lyon RP, et al. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122:1455-1463.
43. Lin K, Tibbitts J, and Shen BQ (2013) Pharmacokinetics and ADME characterizations of antibody-drug conjugates. Methods Mol Biol 1045:117-131.
44. Lorusso PM, Weiss D, Guardino E, Girish S, and Sliwkowski MX (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437-6447.
45. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, and Girish S (2013) An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 52:657-672.
46. Lyon RP, Setter JR, Bovee TD, Doronina SO, Anderson ME, Leiske CL, and Senter PD (2013) Self-stabilizing ADCs: antibody-drug conjugates prepared with maleimido drug-linkers that catalyze their own thiosuccinimide ring hydrolysis (Abstract 4333). Cancer Res 73(Suppl 1):4333 DOI: 10.1158/1538-7445.AM2013-4333.
47. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, and Terakawa S, et al. (2000) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14:1436-1443.
48. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, and Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888-897.
49. Pastuskovas CV, Maruoka EM, Shen BQ, Koeppen H, Doronina SO, Senter PD, and Zioncheck TF (2005) Tissue distribution, metabolism, and excretion of the antibody-drug conjugate Herceptin-monomethyl auristatin E in rats (Abstract 5063), in Proceedings of the Annual Meeting of the American Association for Cancer Research; 2005 Apr 18-20; Anaheim, CA. Vol 46, pp 1195-1196, AACR, Philadelphia. http://www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/1195-d
50. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, and Connors JM, et al. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190-2196.
51. Rhoden JJ and Wittrup KD (2012) Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci 101:860-867.
52. Schmidt MM and Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861-2871.
53. Seattle Genetics (2011) ADCETRIS Prescribing Information, Seattle Genetics, Inc., Bothell, WA.
54. Seattle Genetics (2014) ADCETRIS Product Monograph, Seattle Genetics, Inc., Bothell, WA.
55. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244.
56. Shah DK and Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5:297-305.
57. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, and Chu YW, et al. (2012a) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910.
58. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, and Mai E, et al. (2012b) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189.
59. Strebhardt K and Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473-480.
60. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, and Erickson H (2011) Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22:728-735.
61. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, and Burchmore M, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726.
62. Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, and Prabhu S, et al. (2014) Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. MAbs 6:689-696.
63. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, and Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821.
64. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, and de Vos S, et al. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189.